Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma

There have been significant advances in the treatment of metastatic renal cell carcinoma (mRCC), with immunotherapy (IO)-based combinations as the standard-of-care treatment in the front-line setting. IO in this setting is paired with another IO agent or with a vascular endothelial growth factor rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawsey, Scott J., Ornstein, Moshe C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700734/
https://www.ncbi.nlm.nih.gov/pubmed/34940060
http://dx.doi.org/10.3390/curroncol28060421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700734/
https://www.ncbi.nlm.nih.gov/pubmed/34940060
http://dx.doi.org/10.3390/curroncol28060421

Ejemplares similares